ATE393159T1 - Heterobicyclische pyrazolderivate als kinaseinhibitoren - Google Patents
Heterobicyclische pyrazolderivate als kinaseinhibitorenInfo
- Publication number
- ATE393159T1 ATE393159T1 AT03763818T AT03763818T ATE393159T1 AT E393159 T1 ATE393159 T1 AT E393159T1 AT 03763818 T AT03763818 T AT 03763818T AT 03763818 T AT03763818 T AT 03763818T AT E393159 T1 ATE393159 T1 AT E393159T1
- Authority
- AT
- Austria
- Prior art keywords
- kinase inhibitors
- pyrazole derivatives
- heterobicyclic pyrazole
- heterobicyclic
- derivatives
- Prior art date
Links
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/42—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39617402P | 2002-07-17 | 2002-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE393159T1 true ATE393159T1 (de) | 2008-05-15 |
Family
ID=30115981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03763818T ATE393159T1 (de) | 2002-07-17 | 2003-07-11 | Heterobicyclische pyrazolderivate als kinaseinhibitoren |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1534716B1 (de) |
| JP (1) | JP2006501191A (de) |
| AR (1) | AR040580A1 (de) |
| AT (1) | ATE393159T1 (de) |
| AU (1) | AU2003254337A1 (de) |
| BR (1) | BR0312722A (de) |
| CA (1) | CA2492673A1 (de) |
| DE (1) | DE60320560T2 (de) |
| ES (1) | ES2304531T3 (de) |
| MX (1) | MXPA05000629A (de) |
| TW (1) | TWI284645B (de) |
| WO (1) | WO2004007504A1 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1694686A1 (de) | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinaseinhibitoren |
| TW200526204A (en) | 2004-02-03 | 2005-08-16 | Pharmacia Italia Spa | 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors |
| WO2006023931A2 (en) | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| EP1812439B2 (de) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinaseinhibitoren |
| FR2878442B1 (fr) * | 2004-11-29 | 2008-10-24 | Aventis Pharma Sa | THIENO(2,3-c)PYRAZOLES SUBSTITUES, PROCEDE DE PREPARATION, COMPOSITIONS LES CONTENANT ET UTILISATION |
| FR2882751B1 (fr) * | 2005-03-04 | 2007-09-14 | Aventis Pharma Sa | Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, procede de preparation, compositions les contenant et utilisation |
| JP5303271B2 (ja) | 2005-07-19 | 2013-10-02 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤として有用な１Ｈ−チエノ［２，３−ｃ］ピラゾール化合物 |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP2007380B1 (de) * | 2006-03-30 | 2011-09-14 | Nerviano Medical Sciences S.r.l. | Verwendung eines kinasehemmers zur behandlung von bestimmten resistenten tumoren |
| AU2007240496A1 (en) | 2006-04-19 | 2007-11-01 | Novartis Ag | Indazole compounds and methods for inhibition of CDC7 |
| DE602007008736D1 (de) * | 2006-05-31 | 2010-10-07 | Nerviano Medical Sciences Srl | 1h-furoä3,2-cü pyrazolverbindungen, die sich als kinaseinhibitoren eignen |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| EP2196459B1 (de) | 2007-09-28 | 2016-11-02 | Takeda Pharmaceutical Company Limited | 5-gliedrige heterocyclische verbindung |
| EP2058315A1 (de) | 2007-10-30 | 2009-05-13 | Nerviano Medical Sciences S.r.l. | Als Aurora-Kinase-Inhibitoren aktive 1H-Furo[3,2-C]Pyrazole |
| ES2687450T3 (es) | 2011-03-31 | 2018-10-25 | Carna Biosciences, Inc. | Nuevo derivado de furanona |
| JP2015511598A (ja) | 2012-03-16 | 2015-04-20 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｐａｋ１阻害剤を用いて黒色腫を治療する方法 |
| WO2015008234A1 (en) * | 2013-07-17 | 2015-01-22 | Glenmark Pharmaceuticals S.A. | Bicyclic heterocyclic compounds as ror gamma modulators |
| JP6569908B2 (ja) | 2014-01-31 | 2019-09-04 | カルナバイオサイエンス株式会社 | 抗がん剤組成物 |
| WO2017144546A1 (en) | 2016-02-23 | 2017-08-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma |
| CN110945002B (zh) * | 2017-08-01 | 2021-12-24 | 正大天晴药业集团股份有限公司 | 作为RORγ抑制剂的双环化合物 |
| EP3956446A1 (de) | 2019-04-17 | 2022-02-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Verfahren und zusammensetzungen zur behandlung von durch nlrp3-inflammasom vermittelten il-1-beta-abhängigen erkrankungen |
| CN118767143A (zh) | 2019-12-12 | 2024-10-15 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| WO2021198511A1 (en) | 2020-04-03 | 2021-10-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of sars-cov-2 infection |
| WO2022008597A1 (en) | 2020-07-08 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of infectious diseases |
| CN113072562B (zh) * | 2021-04-06 | 2022-01-14 | 山东大学 | 一种GSK-3β抑制剂及其制备方法与应用 |
| WO2024261302A1 (en) | 2023-06-22 | 2024-12-26 | Institut National de la Santé et de la Recherche Médicale | Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders |
| WO2025078334A1 (en) | 2023-10-09 | 2025-04-17 | Institut National de la Santé et de la Recherche Médicale | Combination of pak1 inhibitors and clk inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4140785A (en) * | 1978-05-08 | 1979-02-20 | E. I. Du Pont De Nemours And Company | N-(benzothienopyrazol)amide antirhinoviral agents |
| US4420476A (en) * | 1982-05-24 | 1983-12-13 | Averst McKenna & Harrison, Inc. | Benzofuro[3,2-c]pyrazol-3-amine derivatives |
| DK1320531T3 (da) * | 2000-08-10 | 2011-01-03 | Pfizer Italia Srl | Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse |
| NZ523656A (en) * | 2000-08-31 | 2004-11-26 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
| WO2002022605A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2003051847A1 (en) * | 2001-12-19 | 2003-06-26 | Smithkline Beecham P.L.C. | (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors |
-
2003
- 2003-07-11 BR BR0312722-2A patent/BR0312722A/pt not_active IP Right Cessation
- 2003-07-11 DE DE60320560T patent/DE60320560T2/de not_active Expired - Fee Related
- 2003-07-11 WO PCT/EP2003/007529 patent/WO2004007504A1/en not_active Ceased
- 2003-07-11 CA CA002492673A patent/CA2492673A1/en not_active Abandoned
- 2003-07-11 ES ES03763818T patent/ES2304531T3/es not_active Expired - Lifetime
- 2003-07-11 JP JP2004520596A patent/JP2006501191A/ja not_active Abandoned
- 2003-07-11 EP EP03763818A patent/EP1534716B1/de not_active Expired - Lifetime
- 2003-07-11 MX MXPA05000629A patent/MXPA05000629A/es not_active Application Discontinuation
- 2003-07-11 AU AU2003254337A patent/AU2003254337A1/en not_active Abandoned
- 2003-07-11 AT AT03763818T patent/ATE393159T1/de not_active IP Right Cessation
- 2003-07-14 TW TW092119120A patent/TWI284645B/zh not_active IP Right Cessation
- 2003-07-16 AR AR20030102551A patent/AR040580A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004007504A1 (en) | 2004-01-22 |
| DE60320560D1 (de) | 2008-06-05 |
| EP1534716A1 (de) | 2005-06-01 |
| BR0312722A (pt) | 2005-05-10 |
| JP2006501191A (ja) | 2006-01-12 |
| EP1534716B1 (de) | 2008-04-23 |
| AU2003254337A1 (en) | 2004-02-02 |
| DE60320560T2 (de) | 2008-12-11 |
| MXPA05000629A (es) | 2005-04-25 |
| AR040580A1 (es) | 2005-04-13 |
| TW200413389A (en) | 2004-08-01 |
| TWI284645B (en) | 2007-08-01 |
| CA2492673A1 (en) | 2004-01-22 |
| ES2304531T3 (es) | 2008-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE393159T1 (de) | Heterobicyclische pyrazolderivate als kinaseinhibitoren | |
| ATE404564T1 (de) | Diazepinoindolderivate als kinaseinhibitoren | |
| ATE452891T1 (de) | Pyrimidopyrimidone als kinaseinhibitoren | |
| ATE520671T1 (de) | Pyrimidin-harnstoff-derivate als kinase-hemmer | |
| IS7599A (is) | Heterósýklískir kínasatálmar | |
| ATE494287T1 (de) | Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase | |
| DE60315516D1 (de) | Pyridazinon-derivate als cdk2-hemmer | |
| ATE455546T1 (de) | Aminotriazol-verbindungen als proteinkinase- hemmer | |
| ATE445613T1 (de) | Indolylmaleimidderivative als proteinkinase-c- inhibitoren | |
| ATE444292T1 (de) | Pyrazolderivate als faktor-xa-inhibitoren | |
| DE60336732D1 (de) | Azaindol-kinaseinhibitoren | |
| ATE395346T1 (de) | Chinazolinderivate als tyrosinkinaseinhibitoren | |
| ATE388148T1 (de) | Chinolinderivate als phosphodiesterase inhibitoren | |
| DE60313872D1 (de) | Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen | |
| DE60315862D1 (de) | Dihydropyridinonderivate als hne-inhibitoren | |
| DE602007014374D1 (de) | Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer | |
| ATE400271T1 (de) | Aryl-pyridinderivate als 11-beta-hsd1-hemmer | |
| IL173200A0 (en) | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors | |
| ATE538097T1 (de) | Als cox-i-inhibitoren geeignete pyrazolderivate | |
| ATE420076T1 (de) | Indozolonderivate als 11b-hsd1-inhibitoren | |
| IL172132A0 (en) | Thienopyridone derivatives as kinase inhibitors | |
| PL378116A1 (pl) | Heterocykliczne inhibitory kinazy | |
| DE60322544D1 (de) | Glycinamid-derivate als raf-kinase-hemmer | |
| ATE509011T1 (de) | Pyrimidinderivate als 11beta-hsd1-inhibitoren | |
| DE602004026905D1 (de) | 2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |